Your browser doesn't support javascript.
loading
A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children.
Kada, Akiko; Fukano, Reiji; Mori, Tetsuya; Kamei, Michi; Tanaka, Fumiko; Ueyama, Junichi; Sekimizu, Masahiro; Osumi, Tomoo; Mori, Takeshi; Koga, Yuhki; Ohki, Kentaro; Fujita, Naoto; Mitsui, Tetsuo; Saito, Akiko M; Hashimoto, Hiroya; Kobayashi, Ryoji.
Afiliación
  • Kada A; Clinical Research Center, NHO Nagoya Medical Center, Nagoya 460-0001, Japan.akiko.kada@nmh.go.jp.
  • Fukano R; Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Mori T; Department of Pediatrics, St. Marianna University School of Medicine Hospital, Kanagawa 216-8511, Japan.
  • Kamei M; Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
  • Tanaka F; Department of Pediatrics, Saiseikai Yokohamashi Nanbu Hospital, Yokoyama 234-0054, Japan.
  • Ueyama J; Department of Pediatrics, Tottori University Hospital, Yonago, Tottori 683-8503, Japan.
  • Sekimizu M; Department of Pediatrics, NHO Nagoya Medical Center, Nagoya 460-0001, Japan.
  • Osumi T; Children's Cancer Center, National Center for Child Health and Development, Tokyo 157-8535, Japan.
  • Mori T; Department of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Kobe 650-0047, Japan.
  • Koga Y; Department of Pediatrics, Graduate School of Medical Sciences Kyushu University, Fukuoka 812-8582, Japan.
  • Ohki K; Department of Pediatric Hematology and Oncology Research, National Center for Child Health and Development, Tokyo 157-8535, Japan.
  • Fujita N; Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima 730-8619, Japan.
  • Mitsui T; Department of Pediatrics, Yamagata University Hospital, Yamagata 990-9585, Japan.
  • Saito AM; Clinical Research Center, NHO Nagoya Medical Center, Nagoya 460-0001, Japan.
  • Hashimoto H; Clinical Research Center, NHO Nagoya Medical Center, Nagoya 460-0001,Japan.
  • Kobayashi R; Department of Pediatrics and Adolescence, Sapporo Hokuyu Hospital, Sapporo 003-0006, Japan.
Acta Med Okayama ; 74(1): 89-94, 2020 Feb.
Article en En | MEDLINE | ID: mdl-32099255
No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/m2/day) for five days plus melphalan (70 mg/m2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma Anaplásico de Células Grandes / Trasplante de Células Madre Hematopoyéticas / Acondicionamiento Pretrasplante Tipo de estudio: Clinical_trials Límite: Adolescent / Child / Humans Idioma: En Revista: Acta Med Okayama Año: 2020 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma Anaplásico de Células Grandes / Trasplante de Células Madre Hematopoyéticas / Acondicionamiento Pretrasplante Tipo de estudio: Clinical_trials Límite: Adolescent / Child / Humans Idioma: En Revista: Acta Med Okayama Año: 2020 Tipo del documento: Article